Base de dados : MEDLINE
Pesquisa : C19.874.871 [Categoria DeCS]
Referências encontradas : 3329 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 333 ir para página                         

  1 / 3329 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29367532
[Au] Autor:Michitsuji T; Horai Y; Sako A; Asano T; Iwanaga N; Izumi Y; Kawakami A
[Ad] Endereço:Department of General and Internal Medicine, National Hospital Organization Nagasaki Medical Center.
[Ti] Título:[A case of mixed connective tissue disease positive for proteinase 3 antineutrophil cytoplasmic antibody in a patient with slowly progressive type 1 diabetes mellitus and chronic thyroiditis].
[So] Source:Nihon Rinsho Meneki Gakkai Kaishi;40(6):467-470, 2017.
[Is] ISSN:1349-7413
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:  A female in her sixties with slowly progressive type 1 diabetes mellitus (SPT1DM) and chronic thyroiditis was referred to our rheumatology department with swelling in her fingers. A prominent atherosclerotic lesion was revealed upon brain magnetic resonance imaging, and she was found to have mixed connective tissue disease (MCTD) positive for proteinase 3 (PR3)-antineutrophil cytoplasmic antibody (ANCA). This rare case of MCTD accompanying SPT1DM and PR3-ANCA suggested that a synergy between MCTD and PR3-ANCA triggers atherosclerosis.
[Mh] Termos MeSH primário: Anticorpos Anticitoplasma de Neutrófilos
Aterosclerose/etiologia
Diabetes Mellitus Tipo 1/complicações
Doença de Hashimoto/complicações
Doença Mista do Tecido Conjuntivo/diagnóstico
Doença Mista do Tecido Conjuntivo/imunologia
Mieloblastina/imunologia
Tireoidite/complicações
[Mh] Termos MeSH secundário: Idoso
Aterosclerose/diagnóstico por imagem
Aterosclerose/imunologia
Encéfalo/diagnóstico por imagem
Progressão da Doença
Feminino
Seres Humanos
Imagem por Ressonância Magnética
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Antineutrophil Cytoplasmic); EC 3.4.21.76 (Myeloblastin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.2177/jsci.40.467


  2 / 3329 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28609832
[Au] Autor:Delivanis DA; Gustafson MP; Bornschlegl S; Merten MM; Kottschade L; Withers S; Dietz AB; Ryder M
[Ad] Endereço:Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905.
[Ti] Título:Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
[So] Source:J Clin Endocrinol Metab;102(8):2770-2780, 2017 Aug 01.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Context: Thyroid immune-related adverse events (irAEs) in patients treated with programmed death receptor-1 (PD-1) blockade are increasingly recognized as one of the most common adverse effects. Our aim was to determine the incidence and examine the potential mechanisms of anti-PD-1-induced thyroid irAEs. Design: Single-center, retrospective cohort study. Patients and Measurements: We studied 93 patients with advanced cancer (ages 24 to 82 years; 60% males) who received at least one infusion of pembrolizumab. Thyroid test results and thyroid imaging modalities were reviewed. Comprehensive 10-color flow cytometry of peripheral blood was performed. Results: Thirteen (14%) thyroid irAEs were observed. Thyroiditis occurred in seven patients (54%), from which four recovered. New onset of hypothyroidism overt/subclinical developed in three patients. Levothyroxine dosing required doubling in three patients with a known history of hypothyroidism. Thyroperoxidase antibodies were positive in the minority of the patients [4/13 (31%)] and diffuse increased 18fludeoxyglucose uptake of the thyroid gland was observed in the majority [7/11 (64%)] of patients. We observed more circulating CD56+CD16+ natural killer (NK) cells and an elevated HLA-DR surface expression in the inflammatory intermediate CD14+CD16+ monocytes in anti-PD-1-treated patients. Conclusions: Thyroid dysfunction is common in cancer patients treated with pembrolizumab. Reversible destructive thyroiditis and overt hypothyroidism are the most common clinical presentations. The mechanism of thyroid destruction appears independent of thyroid autoantibodies and may include T cell, NK cell, and/or monocyte-mediated pathways. Because the thyroid is a frequent target of anti-PD-1 therapies, patients with therapeutically refractory thyroid cancer may be ideal candidates for this treatment.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/efeitos adversos
Antineoplásicos/efeitos adversos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Hipotireoidismo/induzido quimicamente
Neoplasias Pulmonares/tratamento farmacológico
Melanoma/tratamento farmacológico
Tireoidite/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Autoanticorpos/imunologia
Autoantígenos/imunologia
Estudos de Coortes
Feminino
Fluordesoxiglucose F18
Antígenos HLA-DR/imunologia
Seres Humanos
Hipotireoidismo/diagnóstico por imagem
Hipotireoidismo/tratamento farmacológico
Hipotireoidismo/metabolismo
Imunoglobulinas Glândula Tireoide-Estimulantes/imunologia
Iodeto Peroxidase/imunologia
Proteínas de Ligação ao Ferro/imunologia
Células Matadoras Naturais/imunologia
Masculino
Melanoma/secreção
Meia-Idade
Monócitos/imunologia
Tomografia por Emissão de Pósitrons
Compostos Radiofarmacêuticos
Estudos Retrospectivos
Testes de Função Tireóidea
Tireoidite/diagnóstico por imagem
Tireoidite/imunologia
Tireoidite/metabolismo
Tireotropina/metabolismo
Tiroxina/metabolismo
Tiroxina/uso terapêutico
Tri-Iodotironina/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Antineoplastic Agents); 0 (Autoantibodies); 0 (Autoantigens); 0 (HLA-DR Antigens); 0 (Immunoglobulins, Thyroid-Stimulating); 0 (Iron-Binding Proteins); 0 (Radiopharmaceuticals); 06LU7C9H1V (Triiodothyronine); 0Z5B2CJX4D (Fluorodeoxyglucose F18); 9002-71-5 (Thyrotropin); DPT0O3T46P (pembrolizumab); EC 1.11.1.7 (TPO protein, human); EC 1.11.1.8 (Iodide Peroxidase); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170615
[St] Status:MEDLINE
[do] DOI:10.1210/jc.2017-00448


  3 / 3329 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28603207
[Au] Autor:Okiyama N; Tanaka R
[Ad] Endereço:Department of Dermatology, Faculty of Medicine, University of Tsukuba.
[Ti] Título:Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6.
[So] Source:Nihon Rinsho Meneki Gakkai Kaishi;40(2):95-101, 2017.
[Is] ISSN:1349-7413
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Nivolumab is a standard recombinant antibody treatment for patients with malignant melanoma (MM), which functions as an immune checkpoint inhibitor by blocking the programmed cell death-1 (PD-1) pathway in T cells. However, it leads to various immune-related adverse events (irAEs), and also exacerbates underlying autoimmune diseases. Herein we report cases of MM with irAE. Case 1: A 69-year-old woman with MM developed destructive thyroiditis resulting in hypothyroidism after 3 doses of nivolumab, and had been treated with thyroid gland auxiliary therapy. Case 2: A 80-year-old man with MM developed an acute onset of hyperthyroidism after 4 doses of nivolumab. Case 3: A 85-year-old woman with MM developed polyradiculoneuropathy resulting in somatosensory disorder and muscle weakness after 2 doses of nivolumab, and had been treated with intravenous immunoglobulin and oral predonisolone (40 mg/day). Case 4: A 77-year-old man with MM developed psoriasiform dermatitis after local injections of IFN-ß and 11 doses of nivolumab. Case 5: Case 2 also developed psoriasiform dermatitis. We analyzed serum levels of inflammatory cytokines in MM patients before/after treatments with nivolumab. All six patients who developed psoriasiform dermatitis with/without anamnesis of psoriasis after treatment with nivolumab, and all seven patients with other irAE exhibited increased serum IL-6 levels after nivolumab treatment, while decreased serum levels of IL-6 were observed in 5 of 7 non-afflicted MM patients. In addition, MM patients who achieved good responses to nivolumab significantly exhibited decreased serum TNF-α levels after nivolumab treatment compared to progressive MM patients.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/efeitos adversos
Dermatite/etiologia
Interleucina-6/sangue
Psoríase/etiologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Anticorpos Monoclonais/uso terapêutico
Dermatite/sangue
Feminino
Seres Humanos
Hipertireoidismo/sangue
Hipertireoidismo/etiologia
Masculino
Melanoma/tratamento farmacológico
Polirradiculoneuropatia/sangue
Polirradiculoneuropatia/etiologia
Receptor de Morte Celular Programada 1/imunologia
Psoríase/sangue
Linfócitos T/imunologia
Tireoidite/sangue
Tireoidite/etiologia
Fator de Necrose Tumoral alfa/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (IL6 protein, human); 0 (Interleukin-6); 0 (PDCD1 protein, human); 0 (Programmed Cell Death 1 Receptor); 0 (Tumor Necrosis Factor-alpha); 31YO63LBSN (nivolumab)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171015
[Lr] Data última revisão:
171015
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE
[do] DOI:10.2177/jsci.40.95


  4 / 3329 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28440522
[Au] Autor:Tang W; Chen Y; Pan M; Chen L; Zhang L; Wang T; Zhang X; Zhang P; Zheng C; Yu B
[Ad] Endereço:Department of Nutrition, Fudan University Pudong Medical Center, Shanghai 201399, China.
[Ti] Título:[Nutrition management in obese patients with type 2 diabetes mellitus after laparoscopic sleeve gastrectomy].
[So] Source:Zhonghua Wei Chang Wai Ke Za Zhi;20(4):411-416, 2017 Apr 25.
[Is] ISSN:1671-0274
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To explore the value of nutrition management in obese patients with type 2 diabetes mellitus(T2DM) after laparoscopic sleeve gastrectomy(LSG). METHODS: Clinical data of 22 obese T2DM patients undergoing LSG from March 2013 to July 2015 in Fudan University Pudong Medical Center were collected. All the patients strictly followed the specialized instruction by nutritionists: diabetic and low calorie diet 3347.2 to 5020.8 kJ (800 to 1200 kcal) per day before the operation; low calorie liquid diet 2510.4 kJ(600 kcal) per day before operation for promoting gastric emptying; fasting diet before postoperative ventilation; clear liquid diet 1673.6 to 2510.4 kJ (400 to 600 kcal) per day after postoperative ventilation (liquid intake >2000 ml); low fat liquid diet 2928.8 to 3765.6 kJ (700 to 900 kcal) per day (protein 60 g per day at least, 2000 ml liquid) 2 weeks after the operation; semi-liquid diet 1 month after operation and gradually normal diet. All the 22 patients were followed up at 1 week, 1, 3, 6 months after operation on time. Changes of body weight, waist circumference, hip circumference, body mass index(BMI), blood glucose indexes induding fasting blood glucose(FBG), 2-hour postparandial blood glucose(PBG), fasting C-peptide, 2-hour postprandial C-peptide, fasting serum inculin(FINS), 2-hour postprandial inculin(INS), HbAlc, blood pressure and blood lipid indexes were observed and analyzed before and 1 week, 1, 3, 6 months after operation. RESULTS: The average age of 22 patients (10 men and 12 women) was 38.6 years (18 to 66 years). The duration of diabetes varied from 1 month to 15 years. Comorbidity included 12 patients of high blood pressure, 14 of fatty liver, 1 of coronary heart disease, 1 of gout, 1 of chronic thyroiditis and 1 of menstrual disorder. LSG was performed successfully in all the patients and no severe complications and transference to laparotomy occurred. As compared to pre-operation, at 6 months after operation, the average body weight decreased from (103.9±20.2) kg to (80.9±12.6) kg (t=6.294, P=0.000), waist circumference from (118.6±13.8) cm to (96.4±8.0) cm (t=6.331, P=0.000), hip circumference from (116.9±12.6) cm to (104.0±7.7) cm (t=3.854, P=0.000), BMI from (36.2±5.9) kg/m to (27.9±3.5) kg/m (t=5.630, P=0.000), showing a decreasing trend over time. There was no underweight patient after 6 months follow-up. As compared to pre-operation, at 6 months after operation, the average FBG reduced from (7.4±1.4) mmol/L to (6.0±0.9) mmol/L (t=3.172, P=0.003), 2 h PBG from (14.1±4.9) mmol/L to (7.5±2.2) mmol/L (t=7.026, P=0.000), FINS from (160.0±71.9) mIU/L to (43.8±20.8) mIU/L (t=7.259, P=0.000), 2-hour postprandial INS from (437.6±261.4) mIU/L to (140.5±104.6) mIU/L (t=5.858, P=0.000), fasting C-peptide from (1.1±0.6) µg/L to (0.7±0.3) µg/L (t=3.560, P=0.000), 2-hour postprandial C-peptide from (2.5±0.9) µg/L to (1.5±0.7) µg/L (t=3.865, P=0.000), HbAlc from (8.0±1.6)% to (5.9±0.6)% (t=5.953, P=0.000), showing a decreasing trend over time except FBG, 2h postprandial C-peptide and HbAlc(all P<0.05). FBG and 2-hour PBG of 16 patients returned to normal 3 months after the operation. Blood pressure and trigly ceride decreased obviously 6 months after operation compared to pre-operation with significant difference(P<0.05). At 6 months after operation, blood pressure of 8 comorbidity patients with high blood pressure became normal (8/12, 66.7%) and of 4 patients improved(4/12, 33.3%); B ultrasound examination revealed normal in 11 comorbidity patients with fatty liver(11/14,78.6%) and improvement in 3 patients (3/14,15.4%). Blood uric acid of the gout patient and the menstruation of the menstrual disorder patient returned to normal 3 months and 1 month after the operation respectively. CONCLUSION: As for obese patients with T2DM undergoing LSG, reasonable nutrition management is helpful to decrease body weight, and to obtain an ideal improvement of blood glucose and blood lipid levels.
[Mh] Termos MeSH primário: Cirurgia Bariátrica
Glicemia/fisiologia
Diabetes Mellitus Tipo 2/terapia
Dietoterapia/métodos
Gastrectomia
Lipídeos/sangue
Lipídeos/fisiologia
Obesidade/terapia
Resultado do Tratamento
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Pesos e Medidas Corporais
Peptídeo C/sangue
Peptídeo C/fisiologia
Restrição Calórica
Terapia Combinada
Comorbidade
Doença das Coronárias/complicações
Diabetes Mellitus Tipo 2/complicações
Dieta para Diabéticos
Endoscopia
Fígado Gorduroso/complicações
Fígado Gorduroso/cirurgia
Feminino
Alimentos Formulados
Hemoglobina A Glicada/fisiologia
Gota/complicações
Gota/cirurgia
Doença de Hashimoto/complicações
Seres Humanos
Hipertensão/complicações
Hipertensão/cirurgia
Insulina/sangue
Insulina/fisiologia
Masculino
Distúrbios Menstruais/complicações
Distúrbios Menstruais/cirurgia
Meia-Idade
Obesidade/complicações
Assistência Perioperatória/métodos
Tireoidite/complicações
Triglicerídeos/sangue
Triglicerídeos/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (C-Peptide); 0 (Glycated Hemoglobin A); 0 (Insulin); 0 (Lipids); 0 (Triglycerides); 0 (hemoglobin A1c protein, human)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170426
[St] Status:MEDLINE


  5 / 3329 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28323998
[Au] Autor:McLachlan SM; Lesage S; Collin R; Banuelos B; Aliesky HA; Rapoport B
[Ad] Endereço:Thyroid Autoimmune Disease Unit, Cedars-Sinai Medical Center, Los Angeles, California.
[Ti] Título:Genes Outside the Major Histocompatibility Complex Locus Are Linked to the Development of Thyroid Autoantibodies and Thyroiditis in NOD.H2h4 Mice.
[So] Source:Endocrinology;158(4):702-713, 2017 04 01.
[Is] ISSN:1945-7170
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Thyroiditis and autoantibodies to thyroglobulin (TgAb) and thyroid peroxidase (TPOAb) develop spontaneously in NOD.H2h4 mice, a phenotype enhanced by dietary iodine. NOD.H2h4 mice were derived by introducing the major histocompatibility class (MHC) molecule I-Ak from B10.A(4R) mice to nonobese diabetic (NOD) mice. Apart from I-Ak, the genes responsible for the NOD.H2h4 phenotype are unknown. Extending serendipitous observations from crossing BALB/c to NOD.H2h4 mice, thyroid autoimmunity was investigated in both genders of the F1, F2, and the second-generation backcross of F1 to NOD.H2h4 (N2). Medium-density linkage analysis was performed on thyroid autoimmunity traits in F2 and N2 progeny. TgAb develop before TPOAb and were measured after 8 and 16 weeks of iodide exposure; TPOAb and thyroiditis were studied at 16 weeks. TgAb, TPOAb, and thyroiditis, absent in BALB/c and F1 mice, developed in most NOD.H2h4 and in more N2 than F2 progeny. No linkages were observed in F2 progeny, probably because of the small number of autoantibody-positive mice. In N2 progeny (equal numbers of males and females), a chromosome 17 locus is linked to thyroiditis and TgAb and is suggestively linked to TPOAb. This locus includes MHC region genes from B10.A(4R) mice (such as I-Ak and Tnf, the latter involved in thyrocyte apoptosis) and genes from NOD mice such as Satb1, which most likely plays a role in immune tolerance. In conclusion, MHC and non-MHC genes, encoded within the chromosome 17 locus from both B10.A(4R) and NOD strains, are most likely responsible for the Hashimoto disease-like phenotype of NOD.H2h4 mice.
[Mh] Termos MeSH primário: Autoanticorpos/sangue
Iodeto Peroxidase/imunologia
Complexo Principal de Histocompatibilidade/genética
Tireoglobulina/imunologia
Tireoidite/genética
[Mh] Termos MeSH secundário: Animais
Ligação Genética
Tolerância Imunológica/genética
Camundongos
Camundongos Endogâmicos NOD
Tireoidite/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Autoantibodies); 9010-34-8 (Thyroglobulin); EC 1.11.1.8 (Iodide Peroxidase)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170322
[St] Status:MEDLINE
[do] DOI:10.1210/en.2016-1875


  6 / 3329 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28297756
[Au] Autor:Wang S; Luo YF; Cao JL; Zhang H; Shi XH; Liang ZY; Feng RE
[Ad] Endereço:Department of Pathology, Peking Union Medical College Hospital, Beijing 100730, China.
[Ti] Título:[IgG4 immunohistochemistry in Riedle thyroiditis].
[So] Source:Zhonghua Bing Li Xue Za Zhi;46(3):166-169, 2017 Mar 08.
[Is] ISSN:0529-5807
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To observe the histopathological changes and immunohistochemical expression of IgG4 in Riedle thyroiditis (RT) and to study the relationship between RT and IgG4-related diseases (IgG4-RD). A total of 5 RT patients were collected from the Department of Pathology, Peking Union Medical College Hospital during April 2012 to August 2014. The clinical and immunohistochemical features were analyzed in the 5 patients. Histopathologic analysis was performed on hematoxylin and eosin-stained sections. There were one male and four female patients, aged 52 to 78 years (median 59 years). Five cases were characterized by multiple nodules of thyroid, which increased year by year. All patients were found to have surrounding tissue compression symptoms and signs. Two female patients were found to have hypothyroidism. The serum concentration of IgG was elevated in 2 cases, and the serum concentration of IgG was not tested before operation in the remaining patients. By ultrasound, all presented as low echo or medium low echo. Strong echo occasionally appeared in hypoechoic nodules. Microscopically, fibrous tissue hyperplasia was infiltrated with varying numbers of lymphocytes and plasma cells. The occlusion of phlebitis was found in 4 cases and eosinophils were found in 3 cases. IgG4 counts and IgG4/IgG ratios in 5 cases were 20/HPF, 16%; 60/HPF, 82%; 22/HPF, 28%; 400/HPF, 266% and 33/HPF, 71%, respectively. With the similar pathological manifestations between RT and IgG4-RD, immunohistochemical staining shows that the number of IgG4 positive plasma cells and IgG4/IgG ratio of RT are increased in varying degrees. Some cases meet the diagnostic criteria of IgG4-RD, and speculate that some cases of RT belong to IgG4-RD.
[Mh] Termos MeSH primário: Imunoglobulina G/metabolismo
Flebite/patologia
Plasmócitos/patologia
Tireoidite/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Eosinófilos/patologia
Feminino
Seres Humanos
Imunoglobulina G/sangue
Imuno-Histoquímica
Linfócitos/patologia
Masculino
Meia-Idade
Tireoidite/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin G)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0529-5807.2017.03.005


  7 / 3329 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28287203
[Au] Autor:Franzellin F; Lucchin L
[Ad] Endereço:Corresponsabile Campagna Provinciale Iodoprofilassi, Ambulatorio per le Tireopatie, Clinica Villa Melitta, Bolzano.
[Ti] Título:[The iodine prophylaxis: the experience in the Autonomous Province of Bolzano (South Tyrol).]
[Ti] Título:La iodoprofilassi: l'esperienza della Provincia Autonoma di Bolzano (Alto Adige)..
[So] Source:Recenti Prog Med;108(2):90-97, 2017 Feb.
[Is] ISSN:2038-1840
[Cp] País de publicação:Italy
[La] Idioma:ita
[Ab] Resumo:Since ancient times in South Tyrol there was evidence of endemic goitre caused by iodine deficiency. In the early 80's an epidemiological research on adults and primary and secondary school children reported in the least a prevalence of goitre from grade 1 B-3 (WHO) of 23,66% (limits WHO >5%) and an urinary iodine of 10,2 µgI/L. Therefore South Tyrol population presented heavy endemic goitre. In 1982 started a generalized iodine prophylaxis with alimentary iodined salt after an intense prevention campaign. In 1990 it has been done another epidemiological research on primary and secondary school children of the province (neck palpation, thyroid ultrasound, blood and urine tests) which revealed a prevalence of goitre from grade 1 B (WHO) of 1,6% (limits WHO >5%) and an urinary iodine of 137,1 µgI/L. Therefore in South Tyrol there was no more evidence of endemic goitre. In 2001 another research over primary and secondary school children, of the same areas and with the same approaches of the previous researches reported a prevalence of goitre of 1,5% and a median of urinary iodine of 230 µgI/L. On the basis of the data of Istituto Superiore di Sanità (National Institute of Health) can be stated that in the Province of Bolzano there's a low presence of congenital hypothyroidism. It has been observed an increase in the thyroiditis and in the diagnosis of thyroid cancer was marked an accentuation of papillar forms, less aggressive than the follicula. Unfortunately since 2001 no new epidemiological researches were done, due to lack of financial resources and the raising of other sanitary problems of higher priority.
[Mh] Termos MeSH primário: Bócio Endêmico/prevenção & controle
Iodo/administração & dosagem
Cloreto de Sódio na Dieta/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Criança
Feminino
Bócio Endêmico/epidemiologia
Seres Humanos
Iodo/deficiência
Itália/epidemiologia
Masculino
Meia-Idade
Prevalência
Neoplasias da Glândula Tireoide/epidemiologia
Tireoidite/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sodium Chloride, Dietary); 0 (iodized salt); 9679TC07X4 (Iodine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170314
[St] Status:MEDLINE
[do] DOI:10.1701/2636.27100


  8 / 3329 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27818005
[Au] Autor:Wachsmann JW; Ganti R; Peng F
[Ad] Endereço:Department of Radiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9140. Electronic address: Jason.Wachsmann@UTSouthwestern.edu.
[Ti] Título:Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
[So] Source:Acad Radiol;24(1):111-115, 2017 Jan.
[Is] ISSN:1878-4046
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE AND OBJECTIVES: The purposes of this study were to provide a case-based overview of various immune-mediated side effects detected by 18F-Fluorodeoxyglucose (F-18 FDG) positron emission tomography-computed tomography (PET-CT) in the patients receiving ipilimumab immunotherapy for treatment of malignant melanoma, and discuss the importance of recognizing immune-mediated side effects in the use of F-18 FDG PET-CT for monitoring therapeutic effects of ipilimumab on metastatic melanoma. MATERIALS AND METHODS: This is a retrospective case series study of the patients diagnosed with melanoma who were subjected to immunomodulating therapy with ipilimumab. F-18 FDG PET-CT findings were reviewed, and the patients with immune-mediated side effects were selected for further analysis, in conjunction with review of clinical progress notes, the results of laboratory tests, and findings of other imaging tests. RESULTS: Four patients with immune-mediated side effects were identified among the patients being treated with ipilimumab and subjected to F-18 FDG PET-CT for monitoring therapeutic effects. These immune mediated side effects include new findings of abnormal increased FDG uptake associated with immune-mediated pancreatitis and hypophysitis, as well as immune-mediated thyroiditis and colitis reported previously. CONCLUSIONS: Various immune-mediated side effects were detected by F-18 FDG PET-CT in the patients subjected to immunomodulating therapy with ipilimumab. It is essential for the interpreting provider to recognize and differentiate abnormal FDG uptake associated with immune-mediated side effects from hypermetabolic malignant lesions when using F-18 FDG PET-CT for monitoring therapeutic effects of ipilimumab on melanoma lesions.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/efeitos adversos
Antineoplásicos/efeitos adversos
Imunoterapia/métodos
Melanoma/tratamento farmacológico
Neoplasias Cutâneas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Colite/induzido quimicamente
Feminino
Fluordesoxiglucose F18
Seres Humanos
Hipofisite/induzido quimicamente
Imunoterapia/efeitos adversos
Ipilimumab
Masculino
Meia-Idade
Imagem Multimodal/métodos
Pancreatite/induzido quimicamente
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/métodos
Tomografia por Emissão de Pósitrons
Estudos Retrospectivos
Tireoidite/induzido quimicamente
Tomografia Computadorizada por Raios X/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents); 0 (Ipilimumab); 0Z5B2CJX4D (Fluorodeoxyglucose F18)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161108
[St] Status:MEDLINE


  9 / 3329 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27693656
[Au] Autor:Sultanova A; Cistjakovs M; Gravelsina S; Chapenko S; Roga S; Cunskis E; Nora-Krukle Z; Groma V; Ventina I; Murovska M
[Ad] Endereço:Riga Stradins University, A. Kirchenstein Institute of Microbiology and Virology, Latvia. Electronic address: alina.sultanova@rsu.lv.
[Ti] Título:Association of active human herpesvirus-6 (HHV-6) infection with autoimmune thyroid gland diseases.
[So] Source:Clin Microbiol Infect;23(1):50.e1-50.e5, 2017 Jan.
[Is] ISSN:1469-0691
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Viral infections frequently have been cited as important environmental factors implicated in the onset of autoimmune thyroiditis (AIT). The aim of this study was to determine the involvement of HHV-6 infection in the development of autoimmune thyroiditis. METHODS: This study included 45 patients (42 female and 3 male; median age 47.00 IQR 38.50-57.00) with histologically, laboratory, and clinically confirmed autoimmune thyroiditis, as well as 30 autopsied subjects (26 female and 4 male; median age 58.50, IQR 51.50-67.00) without thyroid pathologies and 30 healthy blood donors (25 female and 5 male; median age 33.50, IQR 27.75-44.25) as controls. Results were obtained by applying molecular virology and immunohistochemistry techniques. RESULTS: The presence of persistent HHV-6 infection in AIT patients was significantly higher (p 0.0058) than in the control group (44/45 (98%) vs. 23/30 (77%), respectively). Also, a significantly higher frequency of HHV-6 activation marker (U79/80 mRNA) was found in patients' thyroid gland tissue samples with AIT in comparison with the control group (18/44 (41%) vs. 1/17 (6%), respectively; p 0.0118). The median HHV-6 load was found to be higher in patients with active viral infection than in patients without it (2147, IQR 971-4188 vs. 551, IQR 145-1589 copies/1×10 cells; p 0.003). The presence of HHV-6 antigen expression was demonstrated in intrafollicular cellular clusters and immunohistochemistry indicated thyrocytes in the follicle wall. CONCLUSIONS: These findings provide evidence of strong HHV-6 infection association with AIT development.
[Mh] Termos MeSH primário: Doenças Autoimunes
Herpesvirus Humano 6
Infecções por Roseolovirus/complicações
Infecções por Roseolovirus/virologia
Tireoidite/imunologia
Tireoidite/virologia
[Mh] Termos MeSH secundário: Adulto
Autoanticorpos
Autoantígenos/imunologia
Estudos de Casos e Controles
Feminino
Regulação Viral da Expressão Gênica/fisiologia
Genes Virais
Genoma Viral
Seres Humanos
Iodeto Peroxidase/imunologia
Proteínas de Ligação ao Ferro/imunologia
Masculino
Meia-Idade
Infecções por Roseolovirus/imunologia
Tireoglobulina/imunologia
Glândula Tireoide/virologia
Tireotropina/imunologia
Carga Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Autoantigens); 0 (Iron-Binding Proteins); 9002-71-5 (Thyrotropin); 9010-34-8 (Thyroglobulin); EC 1.11.1.7 (TPO protein, human); EC 1.11.1.8 (Iodide Peroxidase)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170209
[Lr] Data última revisão:
170209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161004
[St] Status:MEDLINE


  10 / 3329 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27647429
[Au] Autor:Stan MN; Sonawane V; Sebo TJ; Thapa P; Bahn RS
[Ad] Endereço:Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA.
[Ti] Título:Riedel's thyroiditis association with IgG4-related disease.
[So] Source:Clin Endocrinol (Oxf);86(3):425-430, 2017 Mar.
[Is] ISSN:1365-2265
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CONTEXT: IgG4-positive (+) plasma cells have been reported in both Riedel's thyroiditis (RT) and Hashimoto's thyroiditis (HT). These cells are the hallmark of IgG4-related disease (IgG4-RD). OBJECTIVE: We sought to determine whether RT is part of IgG4-RD spectrum. DESIGN, SETTING AND PATIENTS: This was a case-control study performed at a tertiary medical centre. We included RT cases from the period 1958 to 2008 that had sufficient paraffin-embedded tissue for IgG4 immunostaining. Controls were patients with HT, age and gender matched, with similar pathology criteria. MAIN OUTCOME MEASURE: The main outcome measures were the intensity of the IgG4 staining and the clinical and histological correlates with IgG4-RD. RESULTS: Six pairs of RT and HT were analysed. The mean age was 44·7 years. In both groups, 5/6 cases had positive IgG4 staining. The mean number of IgG4 + cells/ HPF, normalized to the degree of inflammation, was 3·2 ± 3·0 SD (RT) vs 0·9 ± 0·7 (HT), P = 0·15, for fibrotic areas and 2·1 ± 2·3 SD vs 1·0 ± 0·8 (P = 0·39) for areas with lymphoid aggregates. We found the number of IgG4 +  cells in RT to be inversely correlated with the duration of disease (P = 0·046). Three RT cases had associated comorbidities from the IgG4-RD spectrum while none of the HT cases had such conditions. CONCLUSIONS: Riedel's thyroiditis is a component of IgG4-RD with the density of the IgG4 +  lymphocytic infiltrate being time dependent. In this small study, we did not identify differences in IgG4 infiltration between RT and HT, minimizing the utility of this marker in RT diagnosis.
[Mh] Termos MeSH primário: Imunoglobulina G/análise
Plasmócitos/imunologia
Tireoidite/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Estudos de Casos e Controles
Movimento Celular
Comorbidade
Diagnóstico Diferencial
Feminino
Doença de Hashimoto/diagnóstico
Doença de Hashimoto/patologia
Seres Humanos
Imuno-Histoquímica
Linfócitos/citologia
Masculino
Meia-Idade
Tireoidite/classificação
Tireoidite/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin G)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160921
[St] Status:MEDLINE
[do] DOI:10.1111/cen.13238



página 1 de 333 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde